Quantum BioPharma Featured in CTV News Investigation on Stock Manipulation Allegations

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) was the focus of CTV News' W5 program, which aired Part Three of an investigative series examining the company's allegations of stock spoofing. The episodes detail rising market-manipulation cases in Canada and highlight Quantum's call for accountability in its ongoing legal battle.

The company has filed a USD $700 million lawsuit against CIBC and RBC, alleging stock manipulation practices that have impacted shareholder value. CEO Zeeshan Saeed reaffirmed the company's commitment to defending shareholders and advancing multiple sclerosis research through its biopharmaceutical work. Co-Executive Chair Anthony Durkacz has offered up to USD $7 million for information leading to a final judgment or settlement in the related litigation.

Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., Quantum BioPharma is focused on the research and development of its lead compound, Lucid-MS, a patented new chemical entity shown to prevent and reverse myelin degradation in preclinical models.

The company also invented unbuzzd(TM) and spun out its OTC version to Unbuzzd Wellness Inc., retaining ownership of 20.11% of the company as of March 31, 2025. The agreement includes royalty payments of 7% of sales from unbuzzd(TM) until payments to Quantum BioPharma total $250 million, after which the royalty drops to 3% in perpetuity. Quantum BioPharma retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses.

The company maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or commercial property. The latest news and updates relating to QNTM are available in the company's newsroom at https://ibn.fm/QNTM.

This investigation matters because it highlights growing concerns about market manipulation in Canadian financial markets and the significant impact such practices can have on emerging biotech companies and their shareholders. The $700 million lawsuit against major Canadian banks represents one of the largest such cases in recent memory and could set important precedents for how financial institutions monitor and prevent market manipulation.

For investors, the case underscores the importance of market integrity and the potential risks associated with stock manipulation in the biotech sector, where companies often rely on capital markets to fund expensive research and development. The outcome could influence how regulators approach market surveillance and enforcement in Canada's financial markets.

The investigative series by CTV News brings increased public attention to these issues at a time when market manipulation cases appear to be rising in Canada. Quantum BioPharma's willingness to pursue legal action against major financial institutions demonstrates the company's commitment to protecting shareholder interests while continuing its important work in neurodegenerative disease research.